AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says
FDA approves AbbVie's Juvmo for Parkinson's disease, the first D1/D5 agonist. U.S. launch set for Oct 2026. Get pricing and sales data.
Share
Why It Matters
AbbVie got approval for a new Parkinson's medicine launching next year. This could mean big future sales, so watch if the company hits its sales goals.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.